Quantcast

Industry news that matters to you.  Learn more

Spinal Muscular Atrophy Foundation and Rules-Based Medicine Collaborate on SMA Biomarker Panel

Reading time: 1 – 2 minutes

The Spinal Muscular Atrophy (SMA) Foundation and Rules-based Medicine (RBM) have reached the first milestone in a program to develop a panel of plasma protein biomarkers for SMA using RBM’s Multi-Analyte Profiling (MAP) technology platform.

RBM is confirming plasma protien biomarker candidates previously identified from the multicenter “Biomarkers for SMA” (BforSMA) clinical study, which was sponsored by the SMA Foundation and conducted by BG Medicine. RBM is processing samples on their DiscoveryMAP platform plus an additional set of 70 biomarker assays.

The goals is to create a specific panel of biomarker assays for use in clinical trials exploring new treatments for SMA. Karen Chen, Ph.D., Chief Scientific Officer of the SMA Foundation, said:

Biomarkers are critical to accelerating therapeutic development for any disease. They are even more important for rare diseases like SMA where patient populations are small and mostly consist of children. We are excited to work with RBM to leverage their MAP technology to develop a biomarker panel for SMA that will help evaluate responses to treatments more efficiently and minimize the burden of clinical trials for patients and families.

Source: Spinal Muscular Atrophy Foundation